| Primary |
| Drug Use For Unknown Indication |
18.2% |
| Acute Myocardial Infarction |
17.4% |
| Product Used For Unknown Indication |
15.7% |
| Ischaemic Stroke |
11.2% |
| Myocardial Infarction |
5.9% |
| Cerebrovascular Accident |
5.2% |
| Cerebral Infarction |
4.6% |
| Pulmonary Embolism |
4.0% |
| Retinal Haemorrhage |
2.7% |
| Embolic Stroke |
2.2% |
| Cerebral Artery Embolism |
1.9% |
| Hypertension |
1.6% |
| Deep Vein Thrombosis |
1.4% |
| Anticoagulant Therapy |
1.3% |
| Cerebral Artery Occlusion |
1.3% |
| Thrombosis |
1.2% |
| Antiplatelet Therapy |
1.2% |
| Cerebral Thrombosis |
1.0% |
| Embolism |
1.0% |
| Prophylaxis |
0.9% |
|
| Death |
38.6% |
| Chest Pain |
11.5% |
| Haemorrhage Intracranial |
5.4% |
| Pain |
4.6% |
| Cerebral Haemorrhage |
4.4% |
| Vomiting |
3.6% |
| Haemorrhage |
3.5% |
| Drug Ineffective |
3.3% |
| Hypotension |
2.9% |
| Ventricular Tachycardia |
2.9% |
| Angioedema |
2.8% |
| Ventricular Extrasystoles |
2.8% |
| Dyspnoea |
2.3% |
| Chest Discomfort |
2.0% |
| Respiratory Failure |
1.7% |
| Acute Myocardial Infarction |
1.6% |
| Blood Creatine Phosphokinase Increased |
1.6% |
| Ventricular Fibrillation |
1.6% |
| Extrasystoles |
1.5% |
| Ischaemic Stroke |
1.5% |
|
| Secondary |
| Acute Myocardial Infarction |
16.0% |
| Product Used For Unknown Indication |
13.8% |
| Drug Use For Unknown Indication |
13.6% |
| Pulmonary Embolism |
9.6% |
| Retinal Haemorrhage |
5.8% |
| Myocardial Infarction |
5.5% |
| Thrombosis Prophylaxis |
4.9% |
| Deep Vein Thrombosis |
4.0% |
| Cerebrovascular Accident |
3.7% |
| Cerebral Infarction |
3.1% |
| Macular Degeneration |
2.9% |
| Anticoagulant Therapy |
2.5% |
| Ischaemic Stroke |
2.5% |
| Vena Cava Thrombosis |
2.4% |
| Hypertension |
2.1% |
| Peritoneal Dialysis |
1.7% |
| Renal Vein Thrombosis |
1.6% |
| Cerebral Artery Occlusion |
1.5% |
| Thrombolysis |
1.5% |
| Intraventricular Haemorrhage |
1.4% |
|
| Death |
33.3% |
| Chest Pain |
12.1% |
| Intraocular Pressure Increased |
6.5% |
| Vomiting |
4.8% |
| Hypotension |
3.9% |
| Pain |
3.9% |
| Ventricular Tachycardia |
3.9% |
| Haemorrhage |
3.5% |
| Cns Ventriculitis |
3.0% |
| Vena Cava Thrombosis |
3.0% |
| Blood Creatine Phosphokinase Increased |
2.6% |
| Cerebral Haemorrhage |
2.6% |
| Respiratory Failure |
2.6% |
| Haemorrhage Intracranial |
2.2% |
| Intraventricular Haemorrhage |
2.2% |
| Peritonitis Bacterial |
2.2% |
| Subarachnoid Haemorrhage |
2.2% |
| Wrong Drug Administered |
2.2% |
| Abdominal Pain |
1.7% |
| Angioedema |
1.7% |
|
| Concomitant |
| Product Used For Unknown Indication |
39.6% |
| Drug Use For Unknown Indication |
36.2% |
| Prophylaxis |
2.6% |
| Pain |
2.5% |
| Chemotherapy |
2.0% |
| Multiple Myeloma |
1.9% |
| Hypertension |
1.7% |
| Acute Myeloid Leukaemia |
1.5% |
| Septic Shock |
1.3% |
| Hypotension |
1.2% |
| Metastases To Bone |
1.2% |
| Nuclear Magnetic Resonance Imaging |
1.2% |
| Sepsis |
1.2% |
| Constipation |
1.0% |
| Thrombosis Prophylaxis |
0.9% |
| Anxiety |
0.8% |
| Cellulitis |
0.8% |
| Pancytopenia |
0.8% |
| Anaemia |
0.7% |
| Imaging Procedure |
0.7% |
|
| Vomiting |
24.4% |
| Thrombocytopenia |
11.4% |
| Tumour Lysis Syndrome |
8.9% |
| Weight Decreased |
8.1% |
| Wound Infection Staphylococcal |
5.7% |
| Cerebral Haemorrhage |
4.1% |
| Weight Increased |
4.1% |
| Drug Ineffective |
3.3% |
| Platelet Count Decreased |
3.3% |
| Vision Blurred |
3.3% |
| Brain Oedema |
2.4% |
| Heparin-induced Thrombocytopenia |
2.4% |
| Hypotension |
2.4% |
| Tendon Disorder |
2.4% |
| Unresponsive To Stimuli |
2.4% |
| Vena Cava Thrombosis |
2.4% |
| Ventricular Fibrillation |
2.4% |
| Ventricular Tachycardia |
2.4% |
| Vitreous Haemorrhage |
2.4% |
| Acute Myeloid Leukaemia |
1.6% |
|
| Interacting |
| Thrombosis Prophylaxis |
23.4% |
| Deep Vein Thrombosis |
18.7% |
| Product Used For Unknown Indication |
14.0% |
| Pulmonary Embolism |
14.0% |
| Vena Cava Thrombosis |
14.0% |
| Renal Vein Thrombosis |
9.4% |
| Drug Use For Unknown Indication |
3.5% |
| Acute Myocardial Infarction |
1.8% |
| Ischaemic Stroke |
0.6% |
| Myocardial Infarction |
0.6% |
|
| Hypertension |
72.7% |
| Drug Interaction |
18.2% |
| Myocardial Infarction |
9.1% |
|
